Can a special PET scan spot hidden prostate cancer after focal therapy?

NCT ID NCT07733908

Not yet recruiting Diagnosis Sponsor: Aditya Bagrodia Source: ClinicalTrials.gov ↗

First seen Jul 29, 2026 · Last updated Aug 14, 2026 · Updated 2 times

Summary

This trial investigates whether Posluma, a PSMA-targeted PET scan, can accurately detect any remaining or returning prostate cancer about 12 months after focal therapy. Researchers will compare the scan results with MRI and biopsy data in 22 men with intermediate-risk, organ-confined prostate cancer. The goal is to see if this imaging method could serve as a reliable monitoring tool.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Posluma (flotufolastat F 18) PET scan
What this could lead to: If accurate, Posluma PET could become a non-invasive way to monitor prostate cancer after treatment, reducing the need for biopsies.
What could go wrong: This is a small, early-phase trial with only 22 participants. The scan may not be accurate enough to replace standard monitoring methods.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.